Bacterial biofilms in bronchiectasis of primary ciliary dyskinesia (PCD) in comparison with cystic fibrosis (CF) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012
Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF) Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002
Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
Evolution of the infectious disease in cystic fibrosis (CF) Source: Research Seminar 2008 - Host-pathogen interactions in the lung: implications for treatment of respiratory infections and inflammatory lung diseases Year: 2008
Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005
Differences in airway inflammation between children with primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014
Cystic fibrosis Source: Respipedia Article Year: 2018
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections Source: Eur Respir J 2012; 40: 227-238 Year: 2012
Persistent disruption of ciliated epithelium following paediatric lung transplantation Source: Eur Respir J 2012; 40: 1245-1252 Year: 2012
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003
Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008
Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006
Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017
The spectrum of Nocardia lung disease in cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015
Effect of recurrent growth of aspergillus on lung function in paediatric population with cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018
Temporal progression of fungal microbiota in patients with cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015